Form 4 for PCVX Vaxcyte, Inc.
Accepted 2024-02-20 00:00:00 ET · period of report 2024-02-15 · accession 0001415889-24-004352 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-20 | 2024-02-15 | PCVX | Wassil Jim | COO | M - OptEx | $2.42 | +27.9K | 203.9K | +16% | +$67.6K |
| D | 2024-02-20 | 2024-02-15 | PCVX | Wassil Jim | COO | M - OptEx | $0.00 | -27.9K | 62.6K | -31% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-15 | M | A | 27,917 | $2.42 | 203,852 | D | — | — | |
| 2 | Derivative | Stock Option (right to buy) | 2024-02-15 | M | D | 27,917 | $0.00 | 62,638 | D | $2.42 · — to 2029-12-16 | 27,917 Common Stock | (F1) 1/4 of the shares subject to the option vested on December 1, 2020, and 1/48 of the shares vest monthly thereafter. |